These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

435 related articles for article (PubMed ID: 22500861)

  • 41. New therapeutic options in systemic treatment of advanced cutaneous melanoma.
    Mackiewicz-Wysocka M; Zolnierek J; Wysocki PJ
    Expert Opin Investig Drugs; 2013 Feb; 22(2):181-90. PubMed ID: 23215674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vogt-Koyanagi-Harada-like syndrome after CTLA-4 inhibition with ipilimumab for metastatic melanoma.
    Crosson JN; Laird PW; Debiec M; Bergstrom CS; Lawson DH; Yeh S
    J Immunother; 2015; 38(2):80-4. PubMed ID: 25658618
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial.
    Weber JS; Amin A; Minor D; Siegel J; Berman D; O'Day SJ
    Melanoma Res; 2011 Dec; 21(6):530-4. PubMed ID: 22051508
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Update on the role of ipilimumab in melanoma and first data on new combination therapies.
    Maio M; Di Giacomo AM; Robert C; Eggermont AM
    Curr Opin Oncol; 2013 Mar; 25(2):166-72. PubMed ID: 23299197
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of pembrolizumab for the treatment of melanoma.
    Martin-Liberal J; Kordbacheh T; Larkin J
    Expert Opin Drug Saf; 2015 Jun; 14(6):957-64. PubMed ID: 25927979
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ipilimumab in melanoma patients with brain metastasis: a retro-spective multicentre evaluation of thirty-eight patients.
    Konstantinou MP; Dutriaux C; Gaudy-Marqueste C; Mortier L; Bedane C; Girard C; Thellier S; Jouary T; Grob JJ; Richard MA; Templier C; Sakji L; Guillot B; Paul C; Meyer N
    Acta Derm Venereol; 2014 Jan; 94(1):45-9. PubMed ID: 23824275
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical development of the anti-CTLA-4 antibody tremelimumab.
    Ribas A
    Semin Oncol; 2010 Oct; 37(5):450-4. PubMed ID: 21074059
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Ipilimumab: a novel treatment for metastatic melanoma.
    Culver ME; Gatesman ML; Mancl EE; Lowe DK
    Ann Pharmacother; 2011 Apr; 45(4):510-9. PubMed ID: 21505108
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Immunotherapy for malignant melanoma.
    Zeiser R; Schnitzler M; Andrlova H; Hellige T; Meiss F
    Curr Stem Cell Res Ther; 2012 May; 7(3):217-28. PubMed ID: 22329580
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immune checkpoint inhibitors in melanoma provide the cornerstones for curative therapies.
    Eggermont AM; Maio M; Robert C
    Semin Oncol; 2015 Jun; 42(3):429-35. PubMed ID: 25965361
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prospects for the use of ipilimumab in treating advanced prostate cancer.
    Wei XX; Fong L; Small EJ
    Expert Opin Biol Ther; 2016; 16(3):421-32. PubMed ID: 26698365
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ipilimumab approved for metastatic melanoma.
    Traynor K
    Am J Health Syst Pharm; 2011 May; 68(9):768. PubMed ID: 21515855
    [No Abstract]   [Full Text] [Related]  

  • 53. [Antibody therapies for melanoma].
    Kiniwa Y; Okuyama R
    Nihon Rinsho; 2012 Dec; 70(12):2172-6. PubMed ID: 23259392
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Ipilimumab in melanoma.
    Specenier P
    Expert Rev Anticancer Ther; 2012 Dec; 12(12):1511-21. PubMed ID: 23181437
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Immune checkpoint blockade in patients with melanoma metastatic to the brain.
    Di Giacomo AM; Margolin K
    Semin Oncol; 2015 Jun; 42(3):459-65. PubMed ID: 25965364
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ipilimumab induces simultaneous regression of melanocytic naevi and melanoma metastases.
    Libon F; Arrese JE; Rorive A; Nikkels AF
    Clin Exp Dermatol; 2013 Apr; 38(3):276-9. PubMed ID: 23020081
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Patient responses to ipilimumab, a novel immunopotentiator for metastatic melanoma: how different are these from conventional treatment responses?
    Pennock GK; Waterfield W; Wolchok JD
    Am J Clin Oncol; 2012 Dec; 35(6):606-11. PubMed ID: 21336089
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ipilimumab (Yervoy) and inoperable or metastatic melanoma. More evaluation needed, in both first- and second-line use.
    Prescrire Int; 2015 Apr; 24(159):96. PubMed ID: 25941700
    [No Abstract]   [Full Text] [Related]  

  • 59. Long-lasting responses under treatment with ipilimumab: an argument against maintenance therapy?
    Dick J; Enk A; Hassel JC
    Dermatology; 2015; 230(1):8-10. PubMed ID: 25531526
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Drug therapy of melanoma: anti-CTLA-4 and anti-PD-1 antibodies].
    Robert C; Mateus C
    Bull Acad Natl Med; 2014 Feb; 198(2):297-308. PubMed ID: 26263705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.